ProCE Banner Series

Striking a Balance: The Role of Glucagon Agonism to Improve Obesity and Metabolic Care

Join us for an exciting symposium featuring perspectives and recommendations from 2 renowned obesity experts with extensive experience in research and clinical care. This interactive symposium will disseminate cutting-edge information and expert perspectives on translating practice-changing data on novel therapeutic targets—like glucagon agonism—and treatments for obesity into clinical practice.

Held in conjunction with the American Diabetes Association’s 84th Scientific Sessions. In-person registrants must be registered for the conference. Visit https://professional.diabetes.org/scientific-sessions to register now.

  AMA
  | ANCC
Who Should Attend

This program is intended for endocrinologists, primary care physicians, nurse practitioners, physician associates, and other healthcare professionals who manage patients with obesity.

All Events

Striking a Balance: The Role of Glucagon Agonism to Improve Obesity and Metabolic Care

Past Events

June

23

2024

7:00 PM - 8:30 PM Eastern Time (ET)

In-personVirtual

Hyatt Regency Orlando, 9801 International Drive, Orlando, Florida 32819

Faculty

ProCE Banner Faculty
Jaime Almandoz, MD, MBA, MRCPI, FTOS

Medical Director, Weight Wellness Program
Associate Professor of Internal Medicine
Division of Endocrinology
University of Texas Southwestern Medical Center
Dallas, Texas

ProCE Banner Faculty
Domenica M. Rubino, MD

Director
Washington Center for Weight Management and Research
Arlington, Virginia

Topics

Obesity

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with obesity and related conditions.

Target Audience
This program is intended for endocrinologists, primary care physicians, nurse practitioners, physician associates, and other healthcare professionals who manage patients with obesity. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify management strategies that address the multiple pathophysiologic mechanisms connecting obesity and related comorbidities
  • Summarize the effects of targeting glucagon and its receptors in the treatment of obesity and related comorbidities
  • Evaluate the latest efficacy and safety data for novel treatments in development that target glucagon receptors for the management of obesity and related conditions

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.